Mural Oncology (NASDAQ:MURA) CFO Adam Cutler Sells 7,148 Shares

Mural Oncology PLC (NASDAQ:MURA) CFO Adam Cutler sold 7,148 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $2.09, for a total transaction of $14,939.32. Following the completion of the transaction, the chief financial officer directly owned 99,290 shares in the company, valued at approximately $207,516.10. The trade was a 6.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Mural Oncology Trading Up 0.5%

Shares of MURA stock opened at $2.10 on Tuesday. Mural Oncology PLC has a 12 month low of $0.95 and a 12 month high of $4.74. The stock has a market cap of $36.41 million, a P/E ratio of -0.30 and a beta of 2.93. The company has a 50 day simple moving average of $2.08 and a two-hundred day simple moving average of $2.28.

Mural Oncology (NASDAQ:MURA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.38. As a group, equities analysts forecast that Mural Oncology PLC will post -7.54 earnings per share for the current year.

Institutional Investors Weigh In On Mural Oncology

Institutional investors and hedge funds have recently bought and sold shares of the business. Concurrent Investment Advisors LLC purchased a new stake in shares of Mural Oncology during the first quarter worth about $28,000. Armistice Capital LLC boosted its stake in Mural Oncology by 1.3% in the 1st quarter. Armistice Capital LLC now owns 1,722,000 shares of the company’s stock worth $2,170,000 after purchasing an additional 22,000 shares during the period. Emerald Mutual Fund Advisers Trust purchased a new stake in Mural Oncology during the 2nd quarter valued at approximately $192,000. Quadrature Capital Ltd purchased a new stake in Mural Oncology during the 2nd quarter valued at approximately $98,000. Finally, F m Investments LLC bought a new stake in shares of Mural Oncology during the second quarter valued at approximately $192,000. 80.21% of the stock is owned by institutional investors.

Analyst Ratings Changes

MURA has been the subject of several recent research reports. Wall Street Zen lowered Mural Oncology from a “hold” rating to a “strong sell” rating in a report on Sunday, August 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mural Oncology in a research report on Friday, October 31st. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $12.00.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.